Norman T. Ilowite

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.

Andrew I. Shulman, E. Janssen, M. Son, 2011, Arthritis and rheumatism.

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.

A. Reiff, Y. Chon, D. Lovell, 2009, Arthritis and rheumatism.

HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis

E. Zeggini, I. Tachmazidou, R. Duerr, 2015, Proceedings of the National Academy of Sciences.

2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis

C. Wouters, N. Wulffraat, R. Schneider, 2016, Annals of the rheumatic diseases.